BRPI0910530A2 - Espiro (piperidina-4, 2'-pirrolideno) -1- (3,5- trifluormetilfenil) metilcarboxamidas como antagonistas do receptor de taquicinina nk1 - Google Patents

Espiro (piperidina-4, 2'-pirrolideno) -1- (3,5- trifluormetilfenil) metilcarboxamidas como antagonistas do receptor de taquicinina nk1

Info

Publication number: BRPI0910530A2
Authority: BR; Brazil
Prior art keywords: methylcarboxamides; pyrrolidene; tachykinin; trifluoromethylphenyl; spiro
Prior art date: 2008-05-01

Application number

BRPI0910530-1A

Other languages

English (en)

Inventor

Giuseppe Alvaro

Emiliano Castiglioni

Agostino Marasco

Original Assignee

Glaxo Wellcome Mfg Pte Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-01

Filing date

2009-04-29

Publication date

2015-08-18

2009-04-29 Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd

2015-08-18 Publication of BRPI0910530A2 publication Critical patent/BRPI0910530A2/pt

2020-02-11 Publication of BRPI0910530B1 publication Critical patent/BRPI0910530B1/pt

2021-05-25 Publication of BRPI0910530B8 publication Critical patent/BRPI0910530B8/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Nutrition Science (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0910530A 2008-05-01 2009-04-29 compostos espiro (piperidina-4,2-pirrolideno)-1-(3,5-trifluormetilfenil)metilcarboxamidas, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para o tratamento de depressão, ansiedade, distúrbios do sono ou êmese BRPI0910530B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0808030.1A GB0808030D0 (en)	2008-05-01	2008-05-01	Novel compounds
GB0808030.1		2008-05-01
PCT/EP2009/055190 WO2009133135A1 (en)	2008-05-01	2009-04-29	Spiro (piperidine-4, 2 ' -pyrrolidine) -1- (3, 5- trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists

Publications (3)

Publication Number	Publication Date
BRPI0910530A2 true BRPI0910530A2 (pt)	2015-08-18
BRPI0910530B1 BRPI0910530B1 (pt)	2020-02-11
BRPI0910530B8 BRPI0910530B8 (pt)	2021-05-25

Family

ID=39537192

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0910530A BRPI0910530B8 (pt)	2008-05-01	2009-04-29	compostos espiro (piperidina-4,2-pirrolideno)-1-(3,5-trifluormetilfenil)metilcarboxamidas, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para o tratamento de depressão, ansiedade, distúrbios do sono ou êmese

Country Status (22)

Country	Link
US (2)	US8367692B2 (pt)
EP (1)	EP2300474B1 (pt)
JP (1)	JP5524183B2 (pt)
KR (1)	KR101645743B1 (pt)
CN (1)	CN102083832B (pt)
AU (1)	AU2009242120B2 (pt)
BR (1)	BRPI0910530B8 (pt)
CA (1)	CA2723062C (pt)
CY (1)	CY1113458T1 (pt)
DK (1)	DK2300474T3 (pt)
EA (1)	EA017960B1 (pt)
ES (1)	ES2395571T3 (pt)
GB (1)	GB0808030D0 (pt)
HR (1)	HRP20121018T1 (pt)
IL (1)	IL208917A (pt)
MX (1)	MX2010011985A (pt)
PL (1)	PL2300474T3 (pt)
PT (1)	PT2300474E (pt)
RS (1)	RS52719B (pt)
SI (1)	SI2300474T1 (pt)
WO (1)	WO2009133135A1 (pt)
ZA (1)	ZA201007519B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2484674A1 (en) *	2011-02-02	2012-08-08	Rottapharm S.P.A.	Spiro aminic compounds with NK1 antagonist activity
CN109651368A (zh) *	2018-12-17	2019-04-19	武汉药明康德新药开发有限公司	4-甲酸甲酯-2-氧-1,8-二氮杂螺[4.5]癸烷-8-甲酸叔丁酯的制备方法
MX2022014901A (es)	2020-06-02	2023-01-18	Nerre Therapeutics Ltd	Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9215706D0 (en)	1992-07-23	1992-09-09	Tollpass Limited	Parking toll collecting system
EP0702681A1 (en) *	1993-06-07	1996-03-27	Merck & Co. Inc.	Spiro-substituted azacycles as neurokinin antagonists
EP0912174B1 (en)	1996-07-17	2004-04-28	MERCK & CO., INC.	Alteration of circadian rhythmicity with non-peptidal neurikinin-1 receptor antagonists
US6013652A (en)	1997-12-04	2000-01-11	Merck & Co., Inc.	Spiro-substituted azacycles as neurokinin antagonists
AU7788500A (en)	1999-10-25	2001-05-08	Janssen Pharmaceutica N.V.	Use of substance p antagonists for influencing the circadian timing system
JP2005522436A (ja) *	2002-02-08	2005-07-28	グラクソ　グループ　リミテッド	ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
GB0203022D0 (en) *	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
JP4389478B2 (ja) *	2002-05-29	2009-12-24	田辺三菱製薬株式会社	新規ピペリジン誘導体
JP4380508B2 (ja) *	2003-11-28	2009-12-09	田辺三菱製薬株式会社	医薬組成物
JP2005154380A (ja) *	2003-11-28	2005-06-16	Tanabe Seiyaku Co Ltd	ピペリジン誘導体
KR100877641B1 (ko) *	2003-11-28	2009-01-09	미쓰비시 타나베 파마 코퍼레이션	피페리딘 화합물 및 그의 제조 방법
GB0514707D0 (en) *	2005-07-18	2005-08-24	Glaxo Group Ltd	Chemical compounds

2008
- 2008-05-01 GB GBGB0808030.1A patent/GB0808030D0/en not_active Ceased
2009
- 2009-04-29 WO PCT/EP2009/055190 patent/WO2009133135A1/en not_active Ceased
- 2009-04-29 RS RS20120551A patent/RS52719B/sr unknown
- 2009-04-29 BR BRPI0910530A patent/BRPI0910530B8/pt not_active IP Right Cessation
- 2009-04-29 DK DK09738179.2T patent/DK2300474T3/da active
- 2009-04-29 CN CN2009801257867A patent/CN102083832B/zh not_active Expired - Fee Related
- 2009-04-29 EA EA201071259A patent/EA017960B1/ru not_active IP Right Cessation
- 2009-04-29 HR HRP20121018AT patent/HRP20121018T1/hr unknown
- 2009-04-29 CA CA2723062A patent/CA2723062C/en active Active
- 2009-04-29 SI SI200930430T patent/SI2300474T1/sl unknown
- 2009-04-29 US US12/989,699 patent/US8367692B2/en not_active Expired - Fee Related
- 2009-04-29 MX MX2010011985A patent/MX2010011985A/es active IP Right Grant
- 2009-04-29 EP EP09738179A patent/EP2300474B1/en active Active
- 2009-04-29 PT PT97381792T patent/PT2300474E/pt unknown
- 2009-04-29 PL PL09738179T patent/PL2300474T3/pl unknown
- 2009-04-29 AU AU2009242120A patent/AU2009242120B2/en not_active Ceased
- 2009-04-29 KR KR1020107026865A patent/KR101645743B1/ko not_active Expired - Fee Related
- 2009-04-29 JP JP2011506703A patent/JP5524183B2/ja not_active Expired - Fee Related
- 2009-04-29 ES ES09738179T patent/ES2395571T3/es active Active
2010
- 2010-10-21 ZA ZA2010/07519A patent/ZA201007519B/en unknown
- 2010-10-25 IL IL208917A patent/IL208917A/en active IP Right Grant
2012
- 2012-11-21 US US13/682,889 patent/US8633214B2/en not_active Expired - Fee Related
- 2012-12-17 CY CY20121101226T patent/CY1113458T1/el unknown

Also Published As

Publication number	Publication date
PT2300474E (pt)	2013-01-07
US20130123250A1 (en)	2013-05-16
CY1113458T1 (el)	2016-06-22
EA201071259A1 (ru)	2011-10-31
AU2009242120B2 (en)	2012-05-24
SI2300474T1 (sl)	2013-01-31
US8367692B2 (en)	2013-02-05
EP2300474B1 (en)	2012-10-03
PL2300474T3 (pl)	2013-03-29
US8633214B2 (en)	2014-01-21
CA2723062C (en)	2016-07-05
WO2009133135A1 (en)	2009-11-05
JP5524183B2 (ja)	2014-06-18
BRPI0910530B8 (pt)	2021-05-25
JP2011518861A (ja)	2011-06-30
KR20110015421A (ko)	2011-02-15
HRP20121018T1 (hr)	2013-01-31
MX2010011985A (es)	2011-02-24
ZA201007519B (en)	2011-11-30
KR101645743B1 (ko)	2016-08-04
IL208917A (en)	2014-06-30
EA017960B1 (ru)	2013-04-30
EP2300474A1 (en)	2011-03-30
CA2723062A1 (en)	2009-11-05
GB0808030D0 (en)	2008-06-11
US20110053922A1 (en)	2011-03-03
IL208917A0 (en)	2011-01-31
BRPI0910530B1 (pt)	2020-02-11
ES2395571T3 (es)	2013-02-13
CN102083832B (zh)	2013-06-05
RS52719B (sr)	2013-08-30
DK2300474T3 (da)	2012-12-10
AU2009242120A1 (en)	2009-11-05
CN102083832A (zh)	2011-06-01

Legal Events

Date	Code	Title	Description
2016-04-19	B25A	Requested transfer of rights approved	Owner name: NERRE THERAPEUTICS LIMITED (GB)
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-21	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-05-28	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-09-17	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-01-28	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-02-11	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2026-02-24	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 17A ANUIDADE.
2026-07-07	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2877 DE 24-02-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0815797A2 (pt)	2015-06-16	Compostos 8-azabiciclo[3.2.1]octil-2-hidroxibanzamida como antagonistas de receptor opióide mu
CR8655A (es)	2008-09-09	Compuestos novedosos como moduladores del receptor opioide
IL195110A0 (en)	2009-09-22	Substituted spirocyclic cgrp receptor antagonists
IL198825A0 (en)	2010-02-17	Substituted diazepan compounds as orexin receptor antagonists
DOP2007000068A (es)	2007-10-31	Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
SI2094690T1 (sl)	2011-07-29	Derivati 2-aza-biciklo(3.1.0)heksana kot antagonisti receptorja za oreksin
ZA201000676B (en)	2010-10-27	Pyrrolidine aryl-ether as NK3 receptor antagonists
ZA201001125B (en)	2010-10-27	Pyrrolidine Aryl-Ether as NK3 receptor antagonists
EP2099454A4 (en)	2010-11-10	AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
BRPI0919844A2 (pt)	2019-09-24	compostos de azaindazol como antagonistas do receptor ccr1
EP2214676A4 (en)	2011-08-03	SUBSTITUTED DIAZEPANES AS ANTAGONISTS OF OREXIN RECEPTORS
BRPI0717023A2 (pt)	2014-03-11	Tiazol pirazolopirimidina como antagonistas do receptor de crf1
ZA200903334B (en)	2010-04-28	Substituted diazepan compounds as orexin receptor antagonists
EP2350304A4 (en)	2014-04-16	ANTAGONISTS OF THE GREAT-SIMILAR RECEPTOR 3
BRPI0717937A2 (pt)	2013-12-03	Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0814767A2 (pt)	2015-03-03	Derivados de monoamida como antagonistas do receptor de orexina
BRPI0922303A2 (pt)	2016-01-12	arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos para o uso como antagonistas do receptor de vasopressina v1a
BRPI0720078A2 (pt)	2013-12-24	2-aminoquinolinas como antagonistas de receptores de 5-ht(5a)
IL195903A0 (en)	2009-09-01	Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist
BRPI0822693A2 (pt)	2015-07-07	Derivados de quinuclidina como antagonistas do receptor muscarínico m3
IL209266A0 (en)	2011-01-31	Pyrrolidine derivatives as nk2 receptor antagonists
IL207577A0 (en)	2010-12-30	Pyrrolidine ether derivatives as nk3 receptor antagonists
IL217759A0 (en)	2012-03-29	Pyrrolidine derivatives as nk3 receptor antagonists
ZA201100841B (en)	2011-10-26	Novel compounds active as muscarinic receptor antagonists
IL207700A0 (en)	2010-12-30	3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists